Cyclic GMP in urine to monitor the response of ovarian cancer to therapy
- 1 September 1982
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 89 (9) , 760-764
- https://doi.org/10.1111/j.1471-0528.1982.tb05105.x
Abstract
Guanosine 3':5'-phosphate (cycle GMP) in urine has been used to monitor the response of patients with ovarian cancer to treatment. Changes in the cyclic GMP level appear to correlate well with clinical status in that the disappearance of clinically detectable tumour is associated with a drop in the level whereas a tumour recurrence is associated with an elevation. Serially measured cyclic GMP is valuable for detecting a recurrence of tumour growth in patients in clinical remission and can predate any clinical signs by as much as 10 months. In patients who show no response to treatment, cyclic GMP levels in urine are elevated in the majority of specimens collected.Keywords
This publication has 4 references indexed in Scilit:
- Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.Journal of Clinical Pathology, 1982
- Levels of Adenosine 3′,5′ Cyclic Monophosphate and Guanosine 3′,5′ Cyclic Monophosphate in Single Urine Specimens Collected from a Large Population of Healthy SubjectsAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1982
- Plasma and urine cyclic nucleotide levels in malignant disease and cirrhosis of the liver.Journal of Clinical Pathology, 1979
- THE TREATMENT OF ADVANCED CYSTADENOCARCINOMA OF THE OVARY WITH GESTRONOL AND CONTINUOUS ORAL CYCLOPHOSPHAMIDEBJOG: An International Journal of Obstetrics and Gynaecology, 1979